Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzumab-Based Neoadjuvant Therapy
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2017
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Biomarker; Diagnostic use; Pharmacodynamics; Therapeutic Use
- 14 Sep 2017 Planned End Date changed from 1 Oct 2018 to 1 Dec 2018.
- 14 Sep 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2018.
- 02 Jun 2017 Results (n=10), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology